NCT01680991View on ClinicalTrials.gov

A Study of Obinutuzumab in Chinese Participants With CD20+ Malignant Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions
Lymphocytic Leukemia, Chronic, Diffuse Large B-cell Lymphoma, Follicular Lymphoma
Interventions
DRUG

Obinutuzumab

Multiple doses of obinutuzumab.

Trial Locations (4)

100021

Beijing

100142

Beijing

200025

Shanghai

Unknown

Guangzhou

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT01680991 - A Study of Obinutuzumab in Chinese Participants With CD20+ Malignant Disease | Biotech Hunter | Biotech Hunter